Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)

Patients with EGFR‐mutated non‐small cell lung cancer (NSCLC) exhibit resistance to EGFR‐tyrosine kinase inhibitors (TKIs) within 9–14 months of therapy. Recently, EGFR‐mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the durati...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuma, Yusuke, Morikawa, Kei, Tanaka, Hisashi, Yokoyama, Takuma, Itani, Hidetoshi, Horiuchi, Kazuya, Nakagawa, Hideyuki, Takahashi, Nobumasa, Bessho, Akihiro, Soejima, Kenzo, Kishi, Kazuma, Togashi, Akira, Kanai, Yae, Ueda, Koji, Horimoto, Katsuhisa, Matsutani, Noriyuki, Seki, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360199/
https://www.ncbi.nlm.nih.gov/pubmed/30536780
http://dx.doi.org/10.1111/1759-7714.12923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360199/
https://www.ncbi.nlm.nih.gov/pubmed/30536780
http://dx.doi.org/10.1111/1759-7714.12923

Ejemplares similares